CENTRAL FAX CENTER OCT 0 6 2006

Attorney Docket No. P66567US0 Application No. 09/957,458

Amendments to the claims:

This listing of claims replaces all prior versions, and listings, of claims in the application.

Listing of claims:

Claims 1-17 (canceled).

18 (currently amended): A method for growing stem cells comprising the steps of

providing a stem cell with a supporter cell selected from the group consisting of keratinocytic stem cells, lung and tracheal epithelial cells, bone marrow and hepatic stroma cells, neural-glial precursor cells, tissue cells, and "spore"-like stem cells,

the supporter cell being genetically modified by (i) a vector comprising (i) a gene for interleukines, protooncogenes, oncogenes, cell cycle control genes, signal transduction genes, and/or cell based growth factors and (ii) a tetracycline regulatable expression system, in order to provide externally regulatable interactions between the supporter cell and the stem cell

and

applying an external signal for starting or stopping the interactions.

Attorney Docket No. P66567US0 Application No. 09/957,458

- 19 (canceled).
- 20 (previously presented): The method of claim 18 wherein the interactions are based on secretion or display of substances.
- 21 (previously presented): The method of claim 18 wherein the supporters are modified for the secretion or display of substances under control of a promoter.
- 22 (canceled).
- 23 (previously presented): The method of claim 18, wherein the supporters form a micro-environment.
- 24 (currently amended): The method of claim 18, wherein the supporters are secreting or displaying cell based growth factors[,] protein growth factors and/or interleukines.
- 25 (currently amended): A supporter cell for the use in the method to claim 18, the supporter cell being selected from the group consisting of keratinocytic stem cells, lung and tracheal epithelial cells, bone marrow and hepatic stroma cells, neural-glial precursor cells, tissue cells, and "spore"-like stem cells,

OCT. 6. 2006 6:37PM JACOBSON HOLMAN PLLC

NO. 640 P. 7

Attorney Docket No. P66567US0 Application No. 09/957,458

the supporter cell being genetically modified by (i) a vector comprising (i) a gene for interleukines, protooncogenes, oncogenes, cell cycle control genes, signal transduction genes, and/or cell based growth factors and (ii) a tetracycline regulatable expression system, in order to provide externally regulatable interactions between the supporter cell and the stem cell and,

- the supporter cell being genetically modified in order to provide a regulatable secretion
 and/or a display of substances of the supporter cell.
- 26 (currently amended): A supporter cell for the use in the method to claim 18, the supporter cell being selected from the group consisting of keratinocytic stem cells, lung and tracheal epithelial cells, bone marrow and hepatic stroma cells, neural-glial precursor cells, tissue cells, and "spore"-like stem cells,
 - the supporter cell being genetically modified by (i) a vector comprising (i) a gene for interleukines, protooncogenes, oncogenes, cell cycle control genes, signal transduction genes, and/or cell based growth factors and (ii) a regulatable expression system, in order to provide externally regulatable interactions between the supporter cell and the stem cell and,
 - the supporter cell being genetically modified, genetically mutated, and/or modified using
 molecular and cellular breding in order to change tet-on to tet-off and vice versa, to

Attorney Docket No. P66567US0 Application No. 09/957,458

change oncogenicity, to change trans-lineage-committement, and to change trans-species specificity.

- 27 (previously presented): The supporter cell according to claim 26, wherein the change oncogenicity is SV40Tag to E6/E7, the change in trans-lineage-committeent is brain to skin, and the change in trans-species specificity is mouse to human.
- 28 (currently amended): A cell line obtainable by transforming a cell with a vector,
 - the cell being selected from the group consisting of keratinocytic stem cells, lung and tracheal epithelial cells, bone marrow and hepatic stroma cells, neural-glial precursor cells, tissue cells, and "spore"-like stem cells, and
 - the vector comprising (i) a gene for interleukines, protooncogenes, oncogenes, cell cycle control genes, signal transduction genes, and/or cell based growth factors and (ii) a tetracycline regulatable expression system.